Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Truth in advertising

This article was originally published in The Tan Sheet

Executive Summary

At the Natural Products Association's Natural Marketplace July 20-22 in Las Vegas, the foundation also announces the launch of a truth in advertising program to educate consumers and publishers about laws and regulations, garner support for an industry pledge and create a hotline for reporting questionable claims. The group will review complaints and take "appropriate and necessary action," including referral to the Federal Trade Commission...

You may also be interested in...



Blow Tests FDA’s, Industry’s Patience For Illicit Drug-Related Product Brands

Three months after FDA acted on a trade group's complaint and took enforcement action against an energy beverage firm for marketing its product as an alternative to an illicit street drug, the dietary supplement industry has another opportunity to judge how well the agency responds to a firm using drug jargon to market a product

Fujifilm Demonstrates Health Specialism With European HealthTech Spinout

From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics. 

Financing Quarterly Statistics, Q1 2024

During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel